Jushi Holdings (JUSHF) Fair Value & Analysis
Healthcare · US · Market cap $95.9M
Jushi Holdings
JUSHF · US
Fair value as of: Aug 13, 2026
From 3 valuation models · updated today
Fair value updated Aug 13, 2026, revised from $1.41 to $1.27 (−10.1%) since Jul 25, 2026. Share price −9.2% over the past month.
Below-average quality, screening 200% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case ($0.7458). The market is more pessimistic than our downside scenario.
- A fairly wide model range ($0.7458 to $1.80) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.2510 – $6.86 · fair‑value band $0.7458 – $1.80 · the $0.4223 price screens below the $1.27 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Jushi Holdings (JUSHF) currently trades at $0.4223, while our model-based Fair Value estimate is $1.27, implying the stock looks roughly 200.0% undervalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Jushi Holdings generated revenue of $265M at a net margin of -26.9%. Revenue grew 4.1% year over year. Net debt stands at $182M. Fundamentals as of Aug 13, 2026
Our scenario range runs from $0.7458 (bear case) to $1.80 (bull case); at $0.4223, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 57% below its 52-week high and 57% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 200%, JUSHF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Multiples ($1.45) versus DCF Models ($1.21). Highest evidence: EV/EBITDA (54).
Notify me when JUSHF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jushi Holdings Inc. engages in the retail, distribution, cultivation, and processing of cannabis for medical and adult-use markets in the United States.
Full company description
Jushi Holdings Inc. engages in the retail, distribution, cultivation, and processing of cannabis for medical and adult-use markets in the United States. The company offers flower, vapes, concentrates, infused chews and chocolates, tinctures, capsules, softgels, topicals and RSO, pre-rolls, and infused chocolate bites under the Hijinks, The Bank, The Lab, Tasteology, Uncommon Kind, Nira + Medicinals, Sèche, Shayo, and Carm's Delight Bites brands. It also engages in the sale of bulk raw materials to duly licensed third parties for use in its own finished products. In addition, the company operates medical cannabis dispensaries under the Beyond Hello, Nature's Remedy, and NuLeaf brands. It serves small local dispensaries and large multi-state operators. Jushi Holdings Inc. was founded in 2018 and is headquartered in Boca Raton, Florida.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jushi Holdings reported revenue of $263M in FY2025 versus $209M in FY2021, a compound +5.9%/yr. Reported net income was −$68.6M in FY2025.
Watch JUSHF: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Jushi Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jushi Holdings (JUSHF) overvalued or undervalued?
What is the fair value of JUSHF?
What is the quality score of JUSHF?
What is the revenue of Jushi Holdings (JUSHF)?
What is the net profit margin of JUSHF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jushi Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.